Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), dubbed the "Emperor." The company now holds 34 patented claims across three U.S. patents and has secured protection in China through Patent No. 115279450 B.
The Emperor represents a significant advancement as a fully implantable artificial heart that provides pulsatile flow without requiring an external pneumatic driver. This technology aims to revolutionize treatment options for end-stage heart failure patients, offering enhanced patient flexibility and improved quality of life.
Picard Medical (NYSE American: PMI), maker of the first U.S. and Canadian approved total artificial heart, reported significant Q2 2025 financial results. The company achieved 207% year-over-year revenue growth to $2.13 million, driven by strong U.S. product sales.
The company recently completed its IPO raising $19.5 million in gross proceeds. Despite revenue growth, Picard reported a net loss of $6.72 million in Q2 2025, compared to $4.06 million in Q2 2024, primarily due to increased non-cash debt expenses and derivative losses. The company's operating loss improved 8% to $3.52 million.
For the first half of 2025, revenue increased 3% to $2.74 million, while net loss widened to $12.29 million. Following the IPO, Picard expects to fund operations into 2026, focusing on artificial heart adoption and developing its next-generation Emperor platform.
Picard Medical (NYSE American: PMI), parent company of SynCardia Systems LLC, has announced the appointment of two new members to its Board of Directors following its initial public offering. The company, known for developing the first U.S. and Canadian commercially-approved total artificial heart, has appointed Sam Van and George Ye to strengthen its board leadership.
Sam Van, founder and CEO of SRO Partners, brings extensive capital markets experience from roles at Freedom U.S. Markets, NYSE, and various board positions. George Ye contributes significant medical device industry expertise from leadership positions at Edwards Lifesciences, Abbott Laboratories, and Johnson & Johnson, particularly in global markets.
Picard Medical (NYSE American: PMI) announced that underwriters have fully exercised their over-allotment option for the company's initial public offering. The option resulted in the issuance of an additional 637,500 shares at $4.00 per share, generating gross proceeds of $2.55 million.
The company's shares began trading on the NYSE American on August 29, 2025. WestPark Capital served as Lead Manager and Sole Bookrunner, with Sentinel Brokers as Co-Manager. E.F. Hutton and Uphorizon acted as financial advisors for the offering.
Picard Medical (NYSE American: PMI) announced its upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held from September 8-10, 2025, at the Lotte New York Palace Hotel in a hybrid format featuring both in-person and virtual sessions.
CEO Patrick NJ Schnegelsberg will deliver an in-person company presentation on September 10th at 1:30 pm. The presentation will be webcasted live and available for replay through Picard's website in the Investor Overview/Events section.
Picard Medical (NYSE American: PMI) has successfully completed its Initial Public Offering (IPO), raising $17 million in gross proceeds. The company offered 4,250,000 shares of common stock at $4.00 per share.
Trading of PMI shares commenced on the NYSE American exchange on August 29, 2025. The underwriters, led by WestPark Capital as Lead Manager and Sole Bookrunner, have a 30-day option to purchase up to 637,500 additional shares to cover potential over-allotments.
Picard Medical (NYSE American: PMI) has announced the pricing of its Initial Public Offering, offering 4,250,000 shares of common stock at $4.00 per share, aiming to raise $17 million in gross proceeds. The company, which manufactures the only FDA and Health Canada-approved total artificial heart (STAH), will begin trading on August 29, 2025.
The IPO includes a 30-day over-allotment option for underwriters to purchase up to 637,500 additional shares. WestPark Capital serves as Lead Manager and Sole Bookrunner. The proceeds will fund market expansion in China through SynCardia Medical (Beijing), product R&D including the Emperor system, sales and marketing capabilities enhancement, debt repayment, and general corporate purposes.
Philip Morris International (PMI) announces the relocation of its corporate headquarters to Stamford, Connecticut, with an expected opening in summer 2022. This move is poised to create approximately 200 jobs and contribute around $50 million to the state's economy. The 71,484 square foot facility will serve as a hub for PMI’s Americas region and amplify its commitment to a smoke-free future. PMI aims to transition to a majority smoke-free product portfolio by the end of 2025, with nearly 30% of net revenues coming from non-combustible products as of Q3 2021.
Philip Morris International (PMI) has nominated Dr. Juan José Daboub and Mr. Shlomo Yanai to its Board of Directors, strengthening its leadership as it transitions to a smoke-free future. Jacek Olczak has also been nominated as CEO, effective immediately after the Annual Shareholders Meeting on May 5. Dr. Daboub brings extensive experience in governance and climate adaptation, while Mr. Yanai offers a solid background in pharmaceutical management, having previously led Teva Pharmaceutical Industries. These appointments are part of PMI's strategic plan to innovate smoke-free products.
The Board of Directors of Philip Morris International (NYSE: PM) has declared a quarterly dividend of $1.20 per common share, payable on April 9, 2021, to shareholders of record as of March 22, 2021. The ex-dividend date is set for March 19, 2021. PMI continues its transformation towards a smoke-free future, aiming to replace traditional cigarettes with smoke-free products. As of December 31, 2020, approximately 12.7 million adults have switched to IQOS. For more details, visit www.pmi.com/dividend.